Plasma therapeutics as the foundation. Selective growth around it.
The platform begins with plasma therapeutics and adds specialty-biopharma, biosimilar, and U.S. licensing opportunities only when the product case is strong and the operating burden is manageable.
Specialized barriers demand specialized operating discipline.
Plasma-derived therapies depend on supply reliability, source-material control, process control, viral safety, quality systems, and specialty-market execution. Those barriers shape what FG intends to own directly and what may remain with qualified partners.
- Immunoglobulin opportunities, including IVIG / SCIG categories.
- Selected coagulation-related and plasma-protein therapies.
- Qualified source-plasma and critical raw-material strategy.
- Product-specific fractionation, purification, fill-finish, testing, storage, and cold-chain models.
Programs enter through gates, not enthusiasm.
Initial programs are selected only after diligence and formal approval. The public platform therefore describes priorities rather than presenting unapproved product candidates as committed launches.
Plasma Therapeutics
Clear medical need, workable rights and supply position, manageable CMC and quality risks, and a credible U.S. regulatory and access case.
Specialty Biopharma
Selected opportunities in areas such as oncology, immunology, rare disease, and metabolic disease where evidence and economics are supportable.
Biosimilars
Selected high-value opportunities where patent timing, analytical burden, manufacturing economics, and payer dynamics are workable.
U.S. Licensing
License-in or co-development opportunities that strengthen the platform without creating an operating burden the organization cannot support.
What every program must answer.
Scientific / Clinical
Is the medical rationale strong enough to justify U.S. investment?
Regulatory
Is there a workable FDA pathway and evidence plan?
CMC / Supply
Can the product be manufactured, controlled, and supplied reliably?
IP / Legal
Are rights, freedom to operate, and transaction boundaries understood?
Market Access
Can the product earn a viable place in U.S. reimbursement and clinical pathways?
Financial
Does the risk-adjusted return justify capital and management attention?